Compare SLRC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLRC | SPRY |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.0M | 833.1M |
| IPO Year | 2007 | 2020 |
| Metric | SLRC | SPRY |
|---|---|---|
| Price | $15.65 | $8.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $15.14 | ★ $40.00 |
| AVG Volume (30 Days) | 292.9K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $1.09 | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | $9.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.78 | $6.66 |
| 52 Week High | $17.20 | $18.63 |
| Indicator | SLRC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 50.94 |
| Support Level | $15.62 | $8.05 |
| Resistance Level | $16.61 | $8.63 |
| Average True Range (ATR) | 0.35 | 0.40 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 61.18 | 72.22 |
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.